DCP-001

BIOLOGICAL3 trials

Conditions

Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia in RemissionLeukemic Dendritic Cell VaccinationOvarian Cancer

Phase 1

Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia

MendusAcute Myeloid Leukemia (AML), Leukemic Dendritic Cell Vaccination

Start: 2011-04-30End: 2013-05-31Updated: 2022-10-10

Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment

CompletedNCT04739527

University Medical Center GroningenOvarian Cancer

Start: 2021-06-10End: 2025-12-30Updated: 2026-05-01

Phase 2

Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia

NCT03697707

MendusAcute Myeloid Leukemia in Remission

Start: 2018-10-15End: 2025-12-31Target: 20Updated: 2022-10-10

Journal of Clinical Oncology2026-05-27

Successful induction of tumor-directed immune responses in high grade serious ovarian carcinoma patients after primary treatment using a whole tumor cell vaccine.

Journal of Clinical Oncology2025-05-281 citations

Active Immunotherapy with Vididencel As Maintenance Treatment in MRD+ AML Patients in CR1 Results in Strong Anti-Tumor Immune Responses and Durable Long-Term Survival in Patients with an Immune Competent Immune Profile

Blood2024-11-051 citations

Vaccination Using an Allogeneic Leukemia-Derived Dendritic Cell Vaccine, Maintains and Improves Frequencies of Circulating Antigen Presenting Dendritic Cells Correlating with Relapse Free and Overall Survival in AML Patients

Blood2023-11-022 citations

Induction of Cellular and Humoral Immune Responses Is Associated with Durable Remissions in MRD+ AML-Patients after Maintenance Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Blood2023-11-022 citations

Intradermal Vaccination with Vididencel in MRD+ AML-Patients Leads to Increase in Antigen Presenting Cells and T-Cells to the Injection Site, Visualized Using Imaging Mass Cytometry, Showing Local Immune Cell Interactions Leading to Systemic Immune Responses

Blood2023-11-02

Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001

HemaSphere2023-11-016 citations

672 Induction of specific T-cell responses to tumor associated antigens and induction of B-cell responses in ovarian cancer patients by intradermal injection of vididencel

Regular and Young Investigator Award Abstracts2023-10-31

P1387: TREATMENT WITH A LEUKEMIA-DERIVED DENDRITIC CELL VACCINE INDUCES INNATE AND ADAPTIVE IMMUNE RESPONSE CORRELATING WITH CLINICAL RESPONSE IN AML PATIENTS IN CR1 WITH MEASURABLE RESIDUAL DISEASE

HemaSphere2023-08-011 citations

Abstract 4422: Evaluation of immune response to tumor associated antigens in patients with high grade serous ovarian cancer vaccinated intra-dermally with DCP-001, an allogeneic, cancer cell-based vaccine

Cancer Research2023-04-04

Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

Blood2022-11-152 citations

Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion

Blood2022-11-151 citations

Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in AML Patients Shows MRD Conversion and Improved Survival

Blood2021-11-053 citations

Conversion from MRD Positive to Negative Status in AML Patients in CR1 after Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Blood2020-11-044 citations

Durable Responses and Survival in High Risk AML and MDS Patients Treated with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Blood2019-11-135 citations

DCP-001

Sponsors

Conditions

Phase 1

Phase 2

Related Papers